·
Board-Certified Family Physician & Cannabis Medicine Specialist
·
Cannabis Science
Clinical Insight
A new long-term observational study followed children with severe autism spectrum disorder on purified CBD for an average of 27.6 months. The behavioral improvements seen at three months were maintained – and 40% of patients had their concomitant medications reduced. This post examines what the data shows, where the evidence stops, and what it means for families and clinicians.
What 27 Months of Purified CBD Use Reveals About Severe Autism in Children
The research question was straightforward: do the behavioral improvements seen in children with severe ASD at three months on purified CBD actually last? A research team from Tucumán and Buenos Aires followed that cohort for an average of 27.6 months to find out. Their answer, published June 5, 2026 in Pharmacology Biochemistry and Behavior, is that the improvements held, and in 40% of cases, the children’s other medications could be reduced. That is a longer safety record than almost anything else in the pediatric cannabis literature.
CED Clinical Relevance
Strong Clinical Relevance
Long-term pediatric safety data with CBD is exceptionally rare. This study provides the most extended observational record published for purified CBD in severe ASD, directly relevant to families seeking cannabis medicine options where standard pharmacological alternatives carry metabolic burden.
Autism Spectrum Disorder
Pediatrics
Endocannabinoid System
Long-Term Safety
What You’ll Learn
- Why a 27.6-month follow-up period is significant in the context of pediatric cannabis research, where most studies end at 12 weeks
- What the study found about behavioral improvements, safety, and concomitant medication reduction, and what the data cannot prove
- How the endocannabinoid system’s role in autism informs the biological rationale behind this line of research
- The critical methodological limitations that keep this study in the hypothesis-supporting category rather than the practice-changing one
- What families in Massachusetts and clinicians managing severe ASD can reasonably take from these findings
TL;DR
❇️ A long-term observational study followed 13 children with severe ASD on purified CBD for an average of 27.6 months, the longest safety record for this approach in print
❇️ Behavioral improvements in irritability, social withdrawal, and hyperactivity from the 3-month study were maintained; adverse effects from the early phase did not recur
❇️ Concomitant medications were reduced in 40% of children, a finding relevant to families managing risperidone or aripiprazole burden
❇️ No control group, small n=13 for long-term analysis, caregiver-reported outcomes, meaningful signal, not definitive evidence
⚠ Quality Gate Alerts
-
Small sample: 13 children completed long-term follow-up; statistical power is limited across all reported outcomes
-
No control group: Improvements cannot be attributed to CBD without a comparison arm; natural developmental progression and caregiver expectation effects cannot be excluded
- 35% dropout: 7 of the original 20 children did not complete long-term follow-up; if non-responders or children who experienced problems were more likely to leave, the surviving group’s results would be optimistically skewed
-
Observational design: Caregiver-reported outcomes over multiple years are subject to expectation bias, regression to the mean, and instrument familiarity effects
Study at a Glance
| Study Type | Long-term observational follow-up |
| Sample Size | 20 enrolled; 13 completed 27.6-month follow-up |
| Population | Children and adolescents ages 3–18 with ASD severity levels 2–3, intellectual disability, and treatment-resistant behavioral symptoms |
| Intervention | Purified CBD (no THC) as add-on therapy to existing pharmacological regimen |
| Follow-up Duration | Average 27.6 months (enrollment: January–December 2023; follow-up through June 2025) |
| Primary Outcome | Maintenance of behavioral improvements from the 3-month study phase |
| Key Results | Sustained improvements in irritability, social withdrawal, and hyperactivity; early adverse effects did not recur in long-term follow-up |
| Secondary Finding | Concomitant medications reduced in 40% of patients |
| Institutions | Equipo de Neurodesarrollo INIZIO (Tucumán); Hospital J.M. Ramos Mejía and Hospital de Pediatría J.P. Garrahan (Buenos Aires, Argentina) |
| Published | June 2026, Pharmacology Biochemistry and Behavior (ScienceDirect pii: S0091305726000754) |
Why This Matters
The pediatric cannabis research literature has a duration problem. Most studies of cannabinoids in children end at 12 to 16 weeks, long enough to observe an acute effect, not long enough to know what happens next. Families and clinicians managing severe ASD are making decisions that span years, not months. A study that asks “did the improvements at three months persist at 27 months?” is asking the right question for the right time horizon.
The finding that adverse effects from the early phase did not recur over the longer observation period is also clinically important. Short-term tolerability data is useful; long-term tolerability data is rare. This paper adds to a small but now-growing body of evidence that purified CBD can be administered to children with severe ASD over extended periods without the safety signal worsening. That does not mean it is appropriate for all children or all clinical contexts, but it changes the conversation about risk.
Clinical Summary
Researchers from three Argentine institutions enrolled 20 children between ages 3 and 18 with ASD severity levels 2 and 3, the two highest severity categories under DSM-5 classification. All had intellectual disability and treatment-resistant behavioral symptoms. Purified CBD was added to each child’s existing pharmacological regimen between January and December 2023. Thirteen children completed the extended follow-up through June 2025, with an average observation period of 27.6 months. The study was designed as a follow-up to the same team’s three-month observational study, published in early 2025.
The long-term results mirrored the short-term ones: improvements in irritability, social withdrawal, and hyperactivity, assessed through standardized behavioral rating scales, were maintained or further improved. The researchers found no significant difference between the three-month evaluations and the 26-month evaluations, which the authors interpret as evidence that the early improvements were durable. Mild adverse events that had appeared in the short-term phase, mainly irritability and reduced appetite, did not recur. The study’s most clinically notable secondary finding: concomitant medications were reduced in 40% of the children who completed long-term follow-up. The authors framed this as consistent with, rather than caused by, CBD treatment, an important distinction given the observational design.
What This Paper Does Not Show
The study has no control group. This means there is no way to know, from this data alone, whether the children who continued CBD treatment would have improved to a similar degree through natural developmental progression, caregiver relationship effects, or changes in their broader care environment. The study tracks whether improvements were sustained, it does not establish that CBD was responsible for producing or maintaining them.
The 40% medication reduction is one of the study’s more striking figures, but the paper does not specify which medications were reduced, by how much, or whether the reductions were clinician-driven responses to apparent clinical improvement or made for other reasons. Using that number as evidence that CBD reliably reduces medication burden in ASD would misrepresent the study.
Seven of the original 20 children did not complete long-term follow-up. The paper does not detail why. If families whose children were not responding, or who experienced emerging adverse effects, were more likely to discontinue, the 13 who completed follow-up represent a selectively favorable group. Findings from an observational study should always be understood with that selection effect in mind.
How This Fits the Broader Clinical Conversation
The evidence base for cannabinoids in autism is evolving quickly and unevenly. The 2026 Lancet Psychiatry meta-analysis, the largest review of cannabinoid RCTs in mental health conditions to date, found no benefit for anxiety, depression, or PTSD but specifically noted that cannabinoids might improve symptoms in autism spectrum disorder and a few other conditions. That signal, coming from a skeptical meta-analysis, is meaningful context for this long-term paper.
The endocannabinoid system’s role in autism is a legitimate and active area of research. Multiple studies have found lower circulating endocannabinoid levels, particularly anandamide, in children with ASD compared to neurotypical peers. Animal models have shown that activating the endocannabinoid system can rescue some social deficits. CB1 and CB2 receptors are distributed across the brain regions that govern social behavior, anxiety regulation, and sensory processing, the same domains where autistic individuals often diverge from neurotypical development. The biological rationale for investigating CBD in ASD is well-founded, even if the clinical evidence is still in its early chapters. For a deeper exploration of the ECS-autism connection, see CED Clinic’s ongoing coverage of endocannabinoid system research in autism development.
What makes this study distinct is the use of purified CBD, no THC, over an extended period in a severely affected population. The standard pharmacological alternatives for severe ASD irritability are risperidone and aripiprazole, both FDA-approved, both effective for some patients, and both associated with weight gain, metabolic disturbance, and sedation. The clinical unmet need is real. A 40% medication reduction finding in children already on those agents is the kind of signal that warrants a properly powered randomized trial, not dismissal. For context on existing cannabinoid clinical trials for CBD and autism in children, CED Clinic has covered the evolving research landscape in depth.
Dr. Caplan’s Take
In over twenty years of clinical cannabis medicine and more than 300,000 patient encounters, one of the most consistent frustrations families bring to my practice is this: they’ve read about a study that seemed promising, they tried something based on it, and nothing was followed up. The study ended at 12 weeks and nobody asked what happened at month 14 or month 22. This paper is a direct response to that gap, and that matters independent of what it specifically found.
Twenty-seven months is a different kind of data. It’s the duration of a school year, a therapeutic relationship, a developmental phase. When a research team says the improvements seen at three months were still there at 26 months, and that the safety profile didn’t worsen, they are giving families and clinicians something rare: a timeline. Not just a before-and-after, but a trajectory.
The endocannabinoid system connection is the part I keep coming back to when I talk to families about this research. We know, from multiple independent sources, that children with autism spectrum disorder show lower circulating anandamide levels than neurotypical children. Anandamide is the endogenous ligand for CB1 receptors. Those receptors are densely expressed in the prefrontal cortex, the amygdala, the hippocampus, regions central to emotional regulation, social behavior, and the kind of flexible responsiveness to the environment that is often disrupted in severe ASD. When we ask whether CBD might help, we are not asking about a random intervention. We are asking whether a modulation of a system that appears to be dysregulated in this population might have therapeutic relevance. The answer from this study is a cautious, early, small-sample yes. That is worth taking seriously without overstating it.
The 40% medication reduction finding deserves its own attention. Risperidone and aripiprazole are the only FDA-approved options for irritability in autism, and they carry real costs: weight gain, metabolic disturbance, sedation, and, in some children, a blunted affect that families describe as trading one problem for another. If CBD as an adjunct allows meaningful dose reductions in those agents, even in a meaningful fraction of patients, that is a clinically relevant outcome for everyday practice. I am not ready to say that outcome is established; the study’s design cannot prove causation. But it is the kind of preliminary signal that should drive a well-designed trial, not a dismissal.
For families in Massachusetts and across New England who ask me about purified CBD for a severely autistic child: this study provides context, not a protocol. The formulation here was pharmaceutical-grade and precisely defined, not the variable CBD products available at most dispensaries. The population was carefully characterized. The monitoring was structured. Those are not features of a casual experiment, and they should not be replicated casually at home. What this study does give us is a reason to bring the conversation into clinic rather than leaving it to the internet.
What the field needs next is the randomized controlled trial this data is calling for. A properly powered, placebo-controlled study, ideally in a population that includes North American and European children, with pre-registered outcomes and independent rating, would tell us whether the signal in this observational series is real. Until that study exists, I treat these findings as an honest, careful, and scientifically responsible preliminary report from a team that is doing the right kind of work in a population that has too few options. That’s not a cure headline. It is the slower and more trustworthy version of progress.
What a Careful Reader Should Take Away
This study extends an important but limited observational record. Thirteen children with severe ASD tolerated purified CBD for an average of 27.6 months, maintained their earlier behavioral improvements, and in 40% of cases had their other medications reduced. The study does not prove that CBD caused these outcomes, an observational design without a control group cannot do that. What it can do is provide a safety and maintenance signal over a time frame that no prior published study in this population has documented.
The paper’s honest limitation section, combined with the authors’ explicit call for larger placebo-controlled trials, is a marker of scientific integrity. Preliminary evidence framed with appropriate humility is exactly what should precede a rigorous trial design. The research agenda for CBD in severe ASD is now better defined because of this paper, and that is progress, even if it is not a resolution.
For families, the takeaway is not “CBD works for severe autism.” It is “CBD may be tolerable and maintain behavioral benefits over the long term in some severely affected children, and that question deserves the kind of rigorous study it has not yet received.” For clinicians, this paper belongs in the informed consent conversation, alongside a clear articulation of what we do not know.
Read This Paper Through Eight Different Lenses
A single study can mean different things depending on who is reading it. This card separates the patient takeaway, clinical meaning, skepticism, study critique, prior research context, practical implications, future directions, and likely public misreadings.
How to use this: Choose a lens above to see how the same paper reads from a different evidence, clinical, or practical angle.
Patient Takeaway
This study asked a question most research skips entirely: if your child’s behavior improved at three months on purified CBD, will that still be true at two-plus years? For 13 children with severe autism who stayed in this study through June 2025, the answer is yes, the improvements held. That is not a small thing in a field where most studies stop at 12 weeks and no one asks what happened next.
What this cannot tell you: there was no comparison group, so the study cannot prove that CBD caused or sustained the improvements. Children who did not respond, or who had problems, may have been more likely to stop participating, meaning the 13 who completed follow-up may be a selectively favorable group. The improvements in irritability, social withdrawal, and hyperactivity were rated by caregivers, and caregivers who stayed with a treatment for two years may rate outcomes differently than neutral observers would. If your child has severe ASD and you’re wondering whether this evidence supports a conversation with your physician, the answer is yes. It does not replace that conversation.
Note: This Lens Card is based on the news report and abstract for this paper. The full manuscript was not reviewed, and panel content is limited to the supplied source material.
Clinician’s POV
The 40% concomitant medication reduction is the number that most directly addresses clinical practice. Polypharmacy in severe ASD is a genuine management challenge, risperidone and aripiprazole are effective for some patients but carry weight gain, metabolic disturbance, and sedation as recurring complications. An adjunctive agent that might allow dose reduction in a meaningful subset of patients is worth tracking, even if this study’s design cannot confirm that CBD was responsible.
For patient counseling, the safety framing is useful: adverse effects present in the short-term phase, mainly irritability and appetite changes, did not return over 27.6 months of continued use. That is a defensible basis for telling a family that “we don’t see the early problems worsening over time” without overstating the evidence. The formulation matters: pharmaceutical-grade purified CBD is not equivalent to dispensary CBD, and dosing guidance from this study is not available in the abstract. Practice change is premature. Adding this paper to the informed consent conversation for families asking about CBD in severe ASD is appropriate.
Note: Panel interpretation is limited to the abstract and news report. Full manuscript details, including dosing, specific concomitant medications, and monitoring protocol, were not available for this Lens Card.
A Skeptical Read
The dropout rate deserves the most scrutiny. Seven of 20 enrolled children, 35%, did not complete the long-term follow-up. The study does not explain why. In an open-label study where families self-selected into treatment and chose whether to continue, it is plausible that families who were not seeing benefits, or whose children were having problems, were more likely to stop. If that is true, the remaining 13 represent a best-case cohort rather than the full picture.
Behavioral improvements assessed by caregivers over two or more years are also difficult to interpret without blinding. The same caregivers who committed to the treatment for 27 months are rating whether the treatment worked. That does not mean the ratings are wrong, but it introduces a known source of positive bias that the study design cannot correct. Natural developmental progression, increased caregiver skill in behavioral management, and maturation effects could all contribute to observed improvements in children ages 3 to 18 over a multi-year period without any pharmacological intervention. None of those confounders are accounted for here.
Study Critic
N=13 for the primary long-term analysis is insufficient to draw statistically robust conclusions about any of the reported outcomes. Effect size estimates from a sample this small carry wide confidence intervals, which are not reported in the available abstract. The paper’s framing, “no significant differences were observed between the three-month and 26-month evaluations”, establishes maintenance, not efficacy. The question “did CBD work at 27 months?” cannot be answered by comparing two active-treatment timepoints in the same uncontrolled group.
The 40% concomitant medication reduction is reported as a proportion without specifying which drugs were reduced, by what degree, or under what clinical rationale. A 10% dose reduction in one medication counts the same as a full discontinuation in this accounting. The inference gap between “medications were reduced in 40% of patients” and “CBD enabled medication reduction” is substantial and not addressed by the study design. These are genuine limitations of an appropriately framed observational study, not failures of the researchers, but they mean the paper’s contribution is hypothesis generation rather than evidence of efficacy.
Compared to Past Research
This paper is a direct extension of the same research team’s three-month observational study (PMID 39965749, published early 2025 in Pharmacology Biochemistry and Behavior), which found 90% of 20 enrolled children showed improvement in at least one symptom, with 83.5% of reported symptoms improving in responders. The June 2026 paper asks whether those findings held over time, and in the 13 children who completed long-term follow-up, they did.
More broadly, cannabinoid research in autism has produced an uneven literature. The 2026 Lancet Psychiatry meta-analysis (54 RCTs, 2,477 participants) found no benefit of cannabinoids for anxiety or PTSD but specifically noted that cannabinoids might improve ASD symptoms, an unusual endorsement from a skeptical systematic review. Prior observational studies and small trials have found improvements in behavioral symptoms with CBD-containing formulations, though most used preparations that included THC. The purified CBD design in this study series distinguishes it from that earlier work and addresses pediatric safety concerns specific to THC exposure. This is among the most extended observational follow-up datasets in the purified-CBD-for-ASD literature.
Note: comparison literature cited here is drawn from supplied sources and publicly available evidence. Individual papers were not independently reviewed at the full-text level for this Lens Card.
Practical Considerations
For families in Massachusetts, the practical message is specific: the long-term safety profile for purified CBD in children with severe ASD now has a peer-reviewed record in print. That does not mean the treatment is straightforward to access. Massachusetts medical cannabis law requires physician certification for minors, parental consent, and a qualifying condition determination. The product used in this study was pharmaceutical-grade, a level of standardization that most over-the-counter CBD products, even from licensed dispensaries, do not meet.
For clinicians managing severe ASD in pediatric populations, the 40% medication reduction finding is worth discussing with families who are managing significant side effects from risperidone or aripiprazole. The framing should be honest: this is observational, small-sample, and does not prove causation. But it suggests that the question of adjunctive purified CBD is not settled negatively. Dose and monitoring specifics from this study are not available in the abstract, families should not attempt to replicate this treatment approach without structured physician involvement and ongoing behavioral monitoring. The relevant outcome metrics, irritability, social withdrawal, hyperactivity, are trackable with existing standardized instruments.
Future Directions (Expected)
The study’s authors explicitly call for larger, placebo-controlled trials, and this is the appropriate next step. An adequately powered randomized study would need to enroll several hundred children with ASD severity levels 2-3 across multiple sites, include a placebo arm with identical administration, use independent behavioral raters blinded to treatment condition, and follow participants for at least 12 months from baseline. Pre-registered primary endpoints should include both caregiver-reported and clinician-rated behavioral measures.
The concomitant medication reduction finding warrants a focused secondary study: a trial designed specifically to evaluate whether purified CBD adjunctive therapy allows safe dose reduction of risperidone or aripiprazole in children with severe ASD, with metabolic outcomes tracked over time. That question is more directly actionable for clinical practice than a general behavioral improvement endpoint.
On the mechanistic side, biomarker-level investigation of endocannabinoid tone in responding versus non-responding children, measuring anandamide, 2-AG, and related endocannabinoids before and after CBD initiation, would help determine whether ECS dysregulation in ASD is a predictive marker for treatment response, which would be a clinically meaningful advance in patient selection.
Misreadings & Bad-Faith Takes
Distortion 1: “Study proves CBD cures autism.” This is not what the paper found. The study found that behavioral improvements observed at 3 months were maintained in 13 children who continued purified CBD for an average of 27.6 months. There was no control group. The study cannot establish that CBD caused the improvements, and it makes no claim about cure, reversal, or correction of autism itself. Autism is not a disease to be cured, and the study is not framed that way.
Distortion 2: “CBD is now proven safe for all kids with autism.” This paper assessed one pharmaceutical-grade purified CBD formulation in a specific, carefully characterized population, severe ASD with intellectual disability and treatment-resistant symptoms, in Argentina. The safety observation does not generalize to over-the-counter CBD products, preparations containing THC, or children across the full ASD spectrum. Product quality, dose, and clinical context all matter.
Distortion 3: “Doctors are hiding this natural autism cure from parents.” The study was published openly in a peer-reviewed journal. The same researchers who found promising results also explicitly stated the need for placebo-controlled trials before drawing definitive conclusions. The clinical community is not suppressing this work, the researchers themselves are appropriately calling for replication. This is how science is supposed to operate.
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Source
Researchers at Equipo de Neurodesarrollo INIZIO (Tucumán), Hospital General de Agudos J.M. Ramos Mejía, and Hospital de Pediatría Prof. Dr. J.P. Garrahan (Buenos Aires, Argentina). Long-term follow-up study of purified CBD as add-on therapy in children with severe ASD (severity levels 2-3). Published June 2026 in Pharmacology Biochemistry and Behavior. View source → | News coverage →
Author names to be confirmed from full manuscript before publication. Prior 3-month study: PMID 39965749.
Frequently Asked Questions
What is purified CBD and how is it different from regular CBD oil?
Purified CBD is an isolated form of cannabidiol containing no THC and minimal other cannabinoids. Most commercially available CBD oils are full-spectrum or broad-spectrum, meaning they contain trace amounts of THC and other plant compounds. In pediatric research, purified formulations are preferred because they eliminate any psychoactive exposure from THC. The preparation used in this study was pharmaceutical-grade, a level of standardization that over-the-counter CBD products sold at dispensaries or online typically do not meet. That distinction matters when interpreting the safety findings.
How severe is ASD at levels 2 and 3?
Under DSM-5 classification, ASD severity levels describe how much support a person requires. Level 2 requires “substantial support”, children at this level typically have notable difficulty with verbal and nonverbal communication and marked social challenges even with supports in place. Level 3 requires “very substantial support” and involves severe deficits in communication, very limited social initiation, and significant distress related to changes in routine. Most children in this study also had intellectual disability and treatment-resistant behavioral symptoms, a population with very limited pharmacological options beyond risperidone and aripiprazole.
Why was the average follow-up period 27.6 months if enrollment ran through December 2023?
Children were enrolled at different times between January and December 2023, and the data was collected through June 2025. Children enrolled in January 2023 had approximately 29 months of follow-up; those enrolled later had shorter observation windows. Averaging the follow-up durations across the 13 who completed the long-term phase produced the 27.6-month figure. This staggered enrollment design is common in observational studies and explains why the average is well below the maximum possible follow-up.
What does “concomitant medications reduced in 40% of patients” mean clinically?
It means that in 40% of the children who continued through long-term follow-up, the researchers or supervising clinicians were able to reduce one or more psychiatric or behavioral medications the children were already taking alongside purified CBD. For children with severe ASD, those medications often include risperidone or aripiprazole, both of which carry side effects including weight gain, metabolic changes, and sedation. A meaningful reduction in those agents, if it can be sustained, is clinically significant for quality of life. The study’s design does not prove that CBD caused this reduction, but the finding is directionally important and worth testing in a controlled trial.
Does the endocannabinoid system play a role in autism?
Research suggests it may. Multiple studies have found lower circulating endocannabinoid levels, particularly anandamide, in children with ASD compared to neurotypical children. Animal models of autism have shown that activating the endocannabinoid system can partially rescue social deficits in some cases. CB1 and CB2 receptors are distributed across the brain regions involved in emotional regulation, social behavior, and sensory processing, areas where autistic individuals often differ from neurotypical individuals. The biological plausibility for cannabinoid-based intervention in ASD is grounded, even if the clinical evidence remains preliminary. This is one reason why purified CBD has drawn structured scientific attention rather than just anecdotal interest.
Why did 7 of the 20 enrolled children not complete the long-term follow-up?
The abstract and news report do not explain the reasons for the 7 dropouts. This is a genuine limitation. In open-label observational studies, children who are not responding to treatment, or who experience emerging adverse effects, may be more likely to leave the study. If that pattern holds here, the 13 who completed follow-up would represent a selectively favorable subset, meaning the long-term results could overestimate outcomes in the broader population. The authors appropriately call for placebo-controlled trials, which would include all randomized participants in the analysis regardless of dropout, providing a more complete picture.
Is purified CBD available for pediatric patients in Massachusetts?
Massachusetts medical cannabis law permits pediatric patients to access cannabis-derived products under specific conditions. A certifying physician must determine that the patient has a qualifying medical condition, and parents or guardians must provide consent. Pharmaceutical-grade purified CBD, specifically Epidiolex, is FDA-approved for certain refractory seizure disorders and available by prescription from any licensed prescriber. Other purified or high-CBD products available through Massachusetts dispensaries vary considerably in quality and standardization. Families interested in CBD for a child with severe ASD should consult with a clinician experienced in cannabis medicine before making any changes to the child’s existing pharmacological regimen.
How does this study relate to the 2026 Lancet Psychiatry meta-analysis on cannabinoids and mental health?
The 2026 Lancet Psychiatry meta-analysis reviewed 54 randomized controlled trials across multiple mental health conditions and found no benefit of cannabinoids for anxiety, depression, or PTSD. However, the same review specifically noted that cannabinoids might improve symptoms in autism spectrum disorder, insomnia, Tourette syndrome, and cannabis use disorder. That positive signal for ASD in a broadly skeptical meta-analysis is meaningful context for this long-term observational study. The populations differ, the Lancet review focused on RCTs across adults and mixed populations, while this paper is specifically about severe pediatric ASD with purified CBD over a long follow-up. Both point in the same general direction for ASD.
What were the specific behavioral improvements observed in this study?
The improvements were documented on standardized behavioral rating scales across three primary domains: irritability, social withdrawal, and hyperactivity, all consistent with subscales of the Aberrant Behavior Checklist, the most widely used tool for behavioral assessment in ASD trials. The short-term study from the same research team (PMID 39965749) reported approximately 30% improvement in each of those domains and 50% improvement in restricted and repetitive behaviors. The long-term follow-up found that these improvements were maintained or further improved, with no significant difference between the 3-month and 26-month assessments. These are caregiver-completed scales, which introduces some subjectivity, but they are validated instruments with established reliability in this population.
What should a parent do if they want to explore CBD for their child with severe autism?
The most important first step is a thorough conversation with a physician who understands both the neurological complexity of severe ASD and is familiar with cannabis medicine. Severe ASD with intellectual disability involves multiple medications, behavioral programs, and family dynamics that interact in ways a general practitioner may not fully account for. In Massachusetts, CED Clinic and similar cannabis medicine practices provide evaluation alongside guidance on what the evidence currently supports, what it does not, and how to monitor for effects and adverse events in a child who may not be able to reliably self-report. Families should not adjust or reduce existing medications based on this or any other single study without structured physician involvement and ongoing monitoring.
